Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $58.00 Price Target at Jefferies Financial Group

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective increased by Jefferies Financial Group from $54.00 to $58.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

TARS has been the topic of several other reports. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. The Goldman Sachs Group raised their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Barclays decreased their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Guggenheim reiterated a “buy” rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $63.67.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $43.57 on Thursday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a 50 day simple moving average of $50.14 and a 200-day simple moving average of $43.61. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -11.44 and a beta of 1.05. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, equities analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Institutional Trading of Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Crowley Wealth Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter worth approximately $44,000. R Squared Ltd acquired a new stake in Tarsus Pharmaceuticals during the fourth quarter worth approximately $53,000. FMR LLC raised its holdings in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $166,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.